๐Ÿ”ฌDeep Research

WST โ€” West Pharmaceutical Services ยท catalysts, narrative & risks

ยท20 sourcesWST forecast โ†’

West Pharmaceutical Services (WST) โ€” Research Snapshot as of 2026-10-03

Recent Catalysts (last ~1โ€“3 months)

Portfolio divestiture โ€” SmartDose 3.5mL sale to AbbVie: West completed the sale and transfer of manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System (and associated facilities) to AbbVie, following a $112.5 million sale agreement first announced in January 2026, subject to working-capital and other adjustments. Management framed the move as a strategic refocus toward higher-growth, large-volume on-body drug delivery technologies, noting the divested platform contributed only ~4% of fiscal 2025 revenues. West will continue developing its other SmartDose platforms, including the 10mL system [1].


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’